The article presents two variants of the project portfolio selection and scheduling problem (PPSSP). The primary objective of the PPSSP is to maximise the total portfolio value through the selection and scheduling of a subset of projects subject to various operational constraints. This article describes two recently-proposed, generalised models of the PPSSP [1], [2] and proposes a set of synthetically generated problem instances for each. These datasets can be used by researchers to compare the performance of heuristic and meta-heuristic solution strategies. In addition, the Python program used to generate the problem instances is supplied, allowing researchers to generate new problem instances.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9079686 | PMC |
| http://dx.doi.org/10.1016/j.dib.2022.108208 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
In silico evaluation of bisphosphonates identifies leading candidates for SARS-CoV-2 RdRp inhibition.
J Mol Graph Model
January 2025
School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA 6027, Australia; Department of Health Sciences, University of York, York, YO10 5DD, UK. Electronic address:
The novel coronavirus disease (COVID-19) pandemic has resulted in 777 million confirmed cases and over 7 million deaths worldwide, with insufficient treatment options. Innumerable efforts are being made around the world for faster identification of therapeutic agents to treat the deadly disease. Post Acute Sequelae of SARS-CoV-2 infection or COVID-19 (PASC), also called Long COVID, is still being understood and lacks treatment options as well.
View Article and Find Full Text PDFThe Restylane® portfolio of hyaluronic acid (HA) fillers comprises a broad range of products, each with a unique combination of gel strength/firmness and flexibility. Restylane® Shaype™ (HASHA) is a new HA injectable produced with NASHA-HD™ technology and the most recent addition to the Restylane portfolio. NASHA-HD is an evolution of the NASHA™ platform that adds more HA and uses a more efficient cross-linking even though the degree of modification is kept low.
View Article and Find Full Text PDFMalaysia outbreak survivors retain detectable Nipah antibodies and memory B cells after 25 years.
J Infect
January 2025
Department of Medical Microbiology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur 50603, Malaysia. Electronic address:
Objective: To evaluate the long-term humoral immune response to Nipah virus (NiV) in a cohort of 25 survivors after 25 years of post-infection.
Methods: A total of 25 survivors of NiV infection from the 1998 outbreak were recruited for sample collection. The serum IgG antibody response to NiV antigens, specifically nucleocapsid (N), fusion glycoprotein (F) and attachment glycoprotein (G) was evaluated using ELISA.
Adapting to Change: The Evolution of the Specialty Training Level 3 (ST3) Trauma and Orthopaedics Selection Process Before, During, and After the COVID-19 Pandemic.
Cureus
December 2024
Trauma and Orthopaedics, Queen Elizabeth Hospital Birmingham, Birmingham, GBR.
The selection process for Specialty Training Level 3 (ST3) in trauma and orthopaedics is a pivotal yet challenging step for aspiring orthopaedic surgeons. Drawing on personal experience and research, this paper aims to provide a comprehensive analysis of the ST3 selection process, outlining the key stages, including application submission, portfolio evaluation, and interview performance. With recent changes, such as evolving self-assessment scoring criteria and the introduction of a communication station in 2024, candidates face an increasingly dynamic and competitive landscape.
View Article and Find Full Text PDFRenal denervation for hypertension.
Nat Rev Cardiol
January 2025
Division of Cardiology, Columbia University Irving Medical Center, New York, NY, USA.
Innovative therapies for hypertension are desperately needed given the rising prevalence and falling rates of control of hypertension despite an abundance of available medical therapies. Procedural interventions lower blood pressure without depending on adherence to medications, and endovascular renal denervation (RDN) is the interventional procedure with the best evidence base for the treatment of hypertension. After nearly two decades of study, with major refinements to devices, technique and trial design, two different systems for RDN received approval from the FDA in late 2023 for the treatment of hypertension.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!